A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 476 participants.
Also called NCT05816057
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 476 participants
- Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- Registry
-
NCT05816057
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05816057. Randomized; no masking; primary purpose treatment. Start 2022-07-25 (actual); primary completion 2023-07-25 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Biological)
- semaglutide injection
- Lead sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Record details
- Record id
cardio:ct-nct05816057- Content hash
c37c8e06b9ba2268617d7b2fc1d4ed256c41648cbfb0c63196786a532b6e26c4